ORN Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.55 |
| 52 Week High | €2.19 |
| 52 Week Low | €1.55 |
| Beta | 0.65 |
| 11 Month Change | -10.00% |
| 3 Month Change | -11.03% |
| 1 Year Change | -22.05% |
| 33 Year Change | -49.16% |
| 5 Year Change | -40.80% |
| Change since IPO | -38.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.7% | -0.7% | -0.02% |
| 1Y | -22.1% | -17.2% | 8.2% |
Return vs Industry: ORN underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: ORN underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| ORN volatility | |
|---|---|
| ORN Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: ORN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ORN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Carlos Manuel Arjol | www.oryzon.com |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
| ORN fundamental statistics | |
|---|---|
| Market cap | €98.06m |
| Earnings (TTM) | -€4.37m |
| Revenue (TTM) | €15.20m |
6.5x
P/S Ratio-22.4x
P/E RatioIs ORN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORN income statement (TTM) | |
|---|---|
| Revenue | US$15.83m |
| Cost of Revenue | US$271.80k |
| Gross Profit | US$15.56m |
| Other Expenses | US$20.11m |
| Earnings | -US$4.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 98.28% |
| Net Profit Margin | -28.78% |
| Debt/Equity Ratio | 20.8% |
How did ORN perform over the long term?
See historical performance and comparison